Literature DB >> 31525812

Pleurodesis.

Carla Lamb1, Andrew Li2, Dhaval Thakkar1, Pyng Lee2.   

Abstract

Symptomatic pleural disease, specifically malignant pleural effusion, refractory benign pleural effusion, and pneumothoraces are common diseases that often require therapeutic interventions. The spectrum of management strategies often includes selection of a chemical pleurodesis agent administered in combination with an indwelling pleural catheter or chest tube.Additionally, there is a role for minimally invasive techniques which include medical thoracoscopy or more advanced video-assisted thoracoscopic approaches. Ongoing clinical trials continue to evolve best practices regarding the optimal sclerosant agents and procedural approaches in the management of these diseases. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31525812     DOI: 10.1055/s-0039-1693997

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  3 in total

1.  Iodopovidone pleurodesis for malignant pleural effusions: an updated systematic review and meta-analysis.

Authors:  Valliappan Muthu; Sahajal Dhooria; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Ashutosh N Aggarwal; Ritesh Agarwal
Journal:  Support Care Cancer       Date:  2021-01-30       Impact factor: 3.603

2.  Ultrasound-Guided Midpoint Transverse Process to Pleura Nerve Block for Medical Thoracoscopy: A Case Report.

Authors:  Alessia Pedoto; Or Kalchiem-Dekel; Stephanie Baselice; Bryan C Husta; Meg A Rosenblatt
Journal:  A A Pract       Date:  2020-06

3.  Commentary: The price of pleurodesis: The impact of pleurodesis on lung function.

Authors:  Saurav Adhikari; Siva Raja
Journal:  JTCVS Open       Date:  2021-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.